Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
The Thousand Oaks, Calif.-based company reported first-quarter results on Thursday, including an update on its weight loss drug in development, which led analysts to update their Amgen stock price ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
, opens new tab is laying off more than 10% of its global workforce, an internal memo seen by Reuters on Monday shows, as it grapples with falling sales and an intensifying price war for electric ...
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion. Bristol Myers Squibb agreed to a deal with Repertoire Immune Medicines in which it will pay $65 million ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...